4th Novel Conjugate Summit
March 25, 2025 - March 27, 2025
Boston, Massachusetts, United States
The field of conjugatable drugs is advancing at a rapid pace, with major collaborations like Nurix and Pfizer for antibody-degrader conjugates and Bicycle and Novartis for radiopharmaceuticals, which paves the way towards a new generation of more targeted, safer and efficacious novel conjugated drugs.
The 4th Novel Conjugates Summit is the only event offering comprehensive insights into the latest innovations in bioconjugates. From antibody-degrader conjugates to bispecific ADCs and peptide drug conjugates, join us to delve into each of their value propositions and navigate crucial considerations like target selection, PK/PD profiles, and translation into the clinic.